



NANO2CLINIC

CA17140

Cancer nanomedicine –
from the bench to the
bedside





Growing ideas through networks

COST Action CA17140 Cancer Nanomedicine – from the Bench to the Bedside (NANO2CLINIC) is the first, pan-European interdisciplinary network of representatives from academic institutions and small and medium enterprises (SMEs) including clinical research organizations (CROs) devoted to the development of nanosystems carrying anticancer drugs from their initial design, pre-clinical testing of efficacy, pharmacokinetics, and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies.

Moreover, CA17140 is strongly committed to provide excellence in training European Young Investigators and Innovators and guide them along the pathway towards independent research leadership, with no discrimination whatsoever with respect to nationality, age, or gender.



Sabrina Pricl (Chair, IT)
 Rana Sanyal (WG1 Leader, TR)
 Ivana Vinković Vrček (WG2 Leader, HR)
 Carlo Catapano (WG3 Leader, CH)
 Maria Eugenia Riveiro (WG4 Leader, FR)
 M. Francesca Ottaviani (Grant Awarding Coordinator, IT)
 Joanna Korczynska (Grant Holder Manager, PL)
 Lucia Forzi, Science Officer

Nazende Günday-Türeli (Vice-Chair, DE)
 Tomas Strasak (WG1 Vice-Leader, YR/I, CZ)
 Evgeny Apartsin (WG2 Vice-Leader, YR/I, FR)
 Ulf Kahlert (WG3 Vice-Leader, YR/I, DE)
 Enrico Catalano (WG4 Vice-leader, YR/I, IT)

